To validate the role of CXCL12 in AKT/NF-κB pathway activation by iCAFs, recombinant CXCL12 and CXCL12 neutralizing antibody was supplied in CM and cultured lung cancer cells. This evidence concerns the gene AKT1 and lung carcinoma.